Chemotherapy: what is its role in meningioma?

Sherman, Wendy J.; Raizer, Jeffrey J.

doi:10.1586/ern.12.108

Cited by 26 publications

(17 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from these trials have generally been disappointing. 71 Newer agents such as temozolomide (Temodar, Schering-Plough), 11 an alkylating agent, and iri notecan (Camptosar, Pfizer), 10 a topoisomerase inhibitor, have also recently failed to show any significant efficacy. Additional cytotoxic agents, including hydroxyurea, trabectedin, and some plant-derived agents, have recently been tested for their role in the treatment of refractory meningiomas.…”

Section: Cytotoxic Agentsmentioning

confidence: 99%

“…The PDGF receptors (PDGFRs) are abundantly expressed on meningioma cells, and it is believed that PDGF stimulates meningioma proliferation via autocrine and paracrine mechanisms. 71 Receptor expression levels have also been associated with histological tumor grade. 81 The PDGF promotes meningioma growth mainly via aberrant signaling of one of the two kinase cascades presented above.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Recent developments in chemotherapy for meningiomas: a review

Moazzam

Wagle

Zada

2013

FOC

View full text Add to dashboard Cite

Object Currently, few medical options exist for refractory and atypical/anaplastic meningiomas. New developments in chemotherapeutic options for meningiomas have been explored over the past decade. The authors review these recent developments, with an emphasis on emerging avenues for therapy, clinical efficacy, and adverse effects. Methods A review of the literature was performed to identify any studies exploring recent medical and chemotherapeutic agents that have been or are currently being tested for meningiomas. Results from included preclinical and human clinical trials were reviewed and summarized. Results Current guidelines recommend only 3 drugs that can be used to treat patients with refractory and highgrade meningiomas: hydroxyurea, interferon-α 2B, and Sandostatin long-acting release. Recent developments in the medical treatment of meningiomas have been made across a variety of pharmacological classes, including cytotoxic agents, hormonal agents, immunomodulators, and targeted agents toward a variety of growth factors and their signaling cascades. Promising avenues of therapy that are being evaluated for efficacy and safety include antagonists of platelet-derived growth factor receptor, epidermal growth factor receptor, vascular endothelial growth factor receptor, and mammalian target of rapamycin. Because malignant transformation in meningiomas is likely to be mediated by numerous processes interacting via a complex matrix of signals, combination therapies affecting multiple molecular targets are currently being explored and hold significant promise as adjuvant therapy options. Conclusions Improved understanding of the molecular mechanisms driving meningioma tumorigenesis and malignant transformation has resulted in the targeted development of more specific agents for chemotherapeutic intervention in patients with nonresectable, aggressive, and malignant meningiomas.

show abstract

Section: Cytotoxic Agentsmentioning

confidence: 99%

mentioning

confidence: 99%

Recent developments in chemotherapy for meningiomas: a review

Moazzam

Wagle

Zada

2013

FOC

View full text Add to dashboard Cite

show abstract

“…Subsequent radiation therapy depends on the extent of resection and pathological characteristics. However complete resection can be achieved in only <50% of the patients and for those tumors which recur, progress or are inoperable, the optimal medical therapies are yet to be elucidated [23,24]. Although pre-clinical studies have pinpointed new candidate drugs to stop meningioma growth there are currently no effective medical therapy for meningiomas.…”

Section: Introductionmentioning

confidence: 99%

Decrease in serine protease HtrA1 expression correlates with grade and recurrence in meningiomas

Önder

Arıkök

Seçkin

et al. 2015

Advances in Medical Sciences

View full text Add to dashboard Cite

“…Chemotherapy Aggressive meningioma regrowth after radiotherapy has been a big challenge with few therapeutic options, and limited to only three drugs (hydroxyurea, interferon-a 2B, and Sandostatin long-acting release) in the medical treatment of grade 2/3 meningiomas [9,35,53,54]. So far, there has been no report of chemotherapy for JFMs because of its rarity.…”

Section: Radiotherapy For Jfmmentioning

confidence: 99%

Microsurgical management of primary jugular foramen meningiomas: a series of 22 cases and review of the literature

Tang

Zhang

et al. 2016

Neurosurg Rev

View full text Add to dashboard Cite

This study summarized clinical manifestations, surgical management, histological grading, and long-term outcome of jugular foramen meningiomas (JFMs). Retrospective study was performed in 22 consecutive patients with primary JFMs from January 2004 to October 2010, enrolling 10 men and 12 women with average age of 39.4 (14-57 years). The most common initial symptom is hearing disorder, followed by lower cranial nerve dysfunctions. The tumor was classified into type I (intracranial) in 1, type II (intracranial) in 15, type IV (intracranial-extracranial) in 6, and none type III (extracranial). Surgical approaches mainly included retrosigmoid in 7, far lateral in 10, and juxtacondylar in 5, with some variations. The gross total resection was achieved in 15 cases and subtotal resection in 7. Fourteen patients (63.6 %) developed new or worse neurological deficits immediately after operation, of whom 11 (78.6 %) got alleviation. Postoperatively, keeping airway patency and prevention from aspiration pneumonia is very important. Nasotracheal intubation is much more tolerated than orotracheal intubation for postoperative patient management. WHO grade 2 was found in four cases (18.2 %) and grade 3 in one. During the average time of follow-up in 83.2 months, only one (grade 3) died of tumor regrowth 20 months after surgery and radiosurgery. Five of 17 patients of grade 1 developed tumor regrowth. Radiosurgery provides a good tumor control for tumor regrowth in grade 1, or postoperative grade 2 tumor. In conclusion, JFMs has a favorable long-term overall survival; however, neurological preservation is still challenging, especially low cranial nerves.

show abstract

Chemotherapy: what is its role in meningioma?

Cited by 26 publications

References 55 publications

Recent developments in chemotherapy for meningiomas: a review

Recent developments in chemotherapy for meningiomas: a review

Decrease in serine protease HtrA1 expression correlates with grade and recurrence in meningiomas

Microsurgical management of primary jugular foramen meningiomas: a series of 22 cases and review of the literature

Contact Info

Product

Resources

About